A01916 Summary:

BILL NOA01916
 
SAME ASNo same as
 
SPONSOROrtiz (MS)
 
COSPNSRJacobs, Cook, Colton, Clark, Gunther, Peoples-Stokes, Camara, Millman, Cahill, Englebright, Miller
 
MLTSPNSRBrennan, Farrell, Gottfried, Lupardo, Rivera, Weisenberg
 
Amd SS3216, 3221 & 4303, Ins L
 
Requires that insurance companies provide coverage for surveillance tests for ovarian cancer of insured individuals who are deemed to be at risk for ovarian cancer.
Go to top    

A01916 Actions:

BILL NOA01916
 
01/09/2013referred to insurance
01/08/2014referred to insurance
Go to top

A01916 Floor Votes:

There are no votes for this bill in this legislative session.
Go to top

A01916 Text:



 
                STATE OF NEW YORK
        ________________________________________________________________________
 
                                          1916
 
                               2013-2014 Regular Sessions
 
                   IN ASSEMBLY
 
                                       (Prefiled)
 
                                     January 9, 2013
                                       ___________
 
        Introduced  by  M.  of  A.  ORTIZ, JACOBS, COOK, COLTON, CLARK, GUNTHER,
          PEOPLES-STOKES,  CAMARA,  MILLMAN,  BOYLAND,  CAHILL,  ENGLEBRIGHT  --
          Multi-Sponsored  by -- M. of A.  BRENNAN, FARRELL, GOTTFRIED, LUPARDO,
          RIVERA, WEISENBERG -- read once  and  referred  to  the  Committee  on
          Insurance

 
        AN ACT to amend the insurance law, in relation to providing coverage for
          surveillance tests for ovarian cancer
 
          The  People of the State of New York, represented in Senate and Assem-
        bly, do enact as follows:
 
     1    Section 1. Subsection (i) of section 3216  of  the  insurance  law  is
     2  amended by adding a new paragraph 30 to read as follows:
     3    (30)  Every  policy  that  provides  medical, major-medical or similar
     4  comprehensive-type coverage  shall  provide  coverage  for  surveillance
     5  tests  for  ovarian  cancer  for  an  insured who is at risk for ovarian
     6  cancer. (A) For purposes of this subsection, an insured is deemed to  be
     7  at risk if:
     8    (i) she has a family history of:
     9    1. one or more first-degree relative with ovarian cancer;

    10    2. three or more female relatives with breast cancer; or
    11    3. nonpolyposis colorectal cancer; or
    12    (ii) she tests positive for BRCA1 or BRCA2 mutations.
    13    (B)  For  purposes  of this subsection, surveillance tests for ovarian
    14  cancer shall mean annual screening for ovarian cancer using:
    15    (i) CA-125 serum tumor marker testing;
    16    (ii) transvaginal ultrasound; and
    17    (iii) pelvic examination.
    18    § 2. Subsection (k) of section 3221 of the insurance law is amended by
    19  adding a new paragraph 19 to read as follows:
    20    (19) Every group or blanket policy delivered or issued for delivery in
    21  this state which provides hospital, surgical or medical  coverage  shall
 
         EXPLANATION--Matter in italics (underscored) is new; matter in brackets

                              [ ] is old law to be omitted.
                                                                   LBD04283-01-3

        A. 1916                             2
 
     1  include  coverage  for  surveillance  tests  for  ovarian  cancer for an
     2  insured who is at risk for ovarian cancer.  (A)  For  purposes  of  this
     3  subsection, an insured is deemed to be at risk if:
     4    (i) she has a family history of:
     5    1. one or more first-degree relative with ovarian cancer;
     6    2. three or more female relatives with breast cancer; or
     7    3. nonpolyposis colorectal cancer; or
     8    (ii) she tests positive for BRCA1 or BRCA2 mutations.
     9    (B)  For  purposes  of this subsection, surveillance tests for ovarian

    10  cancer shall mean annual screening for ovarian cancer using:
    11    (i) CA-125 serum tumor marker testing;
    12    (ii) transvaginal ultrasound; and
    13    (iii) pelvic examination.
    14    § 3. Section 4303 of the insurance law is  amended  by  adding  a  new
    15  subsection (jj) to read as follows:
    16    (jj)  A health service corporation or medical expense indemnity corpo-
    17  ration which provides medical, major-medical or  similar  comprehensive-
    18  type  coverage  must provide coverage for surveillance tests for ovarian
    19  cancer for an insured who  is  at  risk  for  ovarian  cancer.  (1)  For
    20  purposes of this subsection, an insured is deemed to be at risk if:
    21    (A) she has a family history of:
    22    (i) one or more first-degree relative with ovarian cancer;

    23    (ii) three or more female relatives with breast cancer; or
    24    (iii) nonpolyposis colorectal cancer; or
    25    (B) she tests positive for BRCA1 or BRCA2 mutations.
    26    (2)  For  purposes  of this subsection, surveillance tests for ovarian
    27  cancer shall mean annual screening for ovarian cancer using:
    28    (A) CA-125 serum tumor marker testing;
    29    (B) transvaginal ultrasound; and
    30    (C) pelvic examination.
    31    § 4. This act shall take effect immediately and  shall  apply  to  any
    32  policy issued, renewed, or modified after such effective date.
Go to top